OncoMatch/Clinical Trials/NCT03952065
IT or IA Infusion of PD1/PDL1/CTLA4 Inhibitors Versus IV for Immunotherapy of Head/Neck Cancers (HNC)
Is NCT03952065 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies PD1/PDL1/CTLA4 inhibitors for head/neck neoplasm.
Treatment: PD1/PDL1/CTLA4 inhibitors — This trial was designed to investigate the survival outcomes, response rates, and safety of patients with advanced Head/Neck Squamous cancer via intra-tumor or intra-artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or their combinations.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: other clinical trials of equipment or drugs
Patients participated in other clinical trials of equipment or drugs (signed informed consent) within 4 weeks
Lab requirements
Blood counts
WBC ≥ 3.0×10E9/L; Hb ≥ 90g/L; PLT ≥ 50×10E9/L; INR < 2.3 or PT < 6 seconds above control; Platelet count < 60000/mm3, prothrombin activity < 50% [excluded]
Kidney function
Cr ≤ 145.5 umul/L; Renal failure / insufficiency requiring hemo- or peritoneal dialysis [excluded]
Liver function
Total bilirubin < 51 μmol/L; Albumin > 28 g/L
Laboratory examination test within 7 days prior to procedure: WBC≥3.0×10E9/L; Hb≥90g/L； PLT ≥50×10E9/L；INR < 2.3 or PT < 6 seconds above control；Cr ≤ 145.5 umul/L；Albumin > 28 g/L；Total bilirubin < 51 μmol/L. Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%). Renal failure / insufficiency requiring hemo-or peritoneal dialysis. Known severe atheromatosis. Known uncontrolled blood hypertension (> 160/100 mm/Hg).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify